Kidney-targeted gene transfer is expected to revolutionize the treatment of renal diseases. Previous gene transfer methods using nonviral vectors administered via renal arterial, pelvic, or ureteric routes into the glomerulus, tubules, or interstitial fibroblasts have resulted in low-level expression for ,1 month. The peritubular capillaries (PTC) network is one of the main targets of kidney transplant rejection and of progressive tubulointerstitial fibrosis, which typifies all progressive renal diseases. To access the PTC, we retrogradely injected a lacZ expression plasmid in Ringer's solution into the renal vein of rats. We detected lacZ expression exclusively in the interstitial fibroblasts near the PTC of the injected kidney by immunoelectron microscopic analysis. Nephrotoxicity attributable to gene transfer was not apparent. We then used a rat erythropoietin (Epo) expression plasmid vector, pCAGGS-Epo, in a reporter assay. We obtained maximal Epo expression when the DNA solution was injected within 5 sec, and with a volume of 1.0 ml. We observed a dose-response relationship between serum Epo levels and the amount of injected DNA up to 100 mg. We detected the transgenederived Epo mRNA by reverse transcription polymerase chain reaction only in the kidneys injected with pCAGGS-Epo. After an injection of 100 mg of pCAGGS-Epo, the serum Epo levels peaked at 208.3 6 71.8 mU/ml at week 5, and gradually decreased to 116.2 6 38.7 mU/ml at week 24. A similar pattern was obtained using smaller doses of plasmid, 2 mg or 30 mg of pCAGGS-Epo. Transgene-derived Epo secretion resulted in significant erythropoiesis. This novel technique is simple and safe, allowing high-level and long-term stable gene expression specific to the fibroblasts near the PTC, and should have therapeutic value for future applications in humans.
INTRODUCTION K
IDNEY-TARGETED GENE TRANSFER has the potential to be one of the most important tools for broadening our un-derstanding of renal disease processes and for revolutionizing the treatment of renal diseases. Various methods of kidney-targeted gene transfer have been reported, but the protein levels and duration of expression have not been sufficient for therapeutic use (Tomita et al., 1992; Isaka et al., 1993; Arai et al., 1995; Boletta et al., 1997; Lai et al., 1997 Lai et al., , 1998 Tsujie et al., 2000; Foglieni et al., 2000) . Peritubular (postglomerular) capillaries (PTC) of the kidney, which comprise a network of interstitial vessels that connects veins at every cortical level, play a major role in maintaining renal function and hemodynamics (Dworkin et al., 2000) . Progressive tubulointerstitial fibrosis accompanied by the loss of PTC and tubules typifies all progressive renal diseases (Eddy, 1996) . The severity of chronic tubulointerstitial changes rather than glomerular damage is the single best histologic correlate of decline in renal function and long-term prognosis (Risdon et al., 1968; Schainuck et al., 1970; Serón et al., 1990; Bohle et al., 1996; Thomas et al., 1998; Ohashi et al., 2000) . The endothelium of the PTC is, moreover, one of the main targets of acute and chronic renal transplant rejection (Collins et al., 1999; Shimizu et al., 2000; Mauiyyedi et al., 2001) . Thus, the interstitium containing the PTC network represents an important candidate site for kidney-targeted gene transfer.
The systemic intravenous route is not efficient for kidneytargeted gene transfer, because most of the cationic lipid/DNA complex becomes trapped in the pulmonary tissue and vascular endothelial cells (Zhu et al., 1993) . The local route to the kidney and the kind of nonviral vectors used principally determine the transgene expression sites (Tomita et al., 1992; Isaka et al., 1993; Arai et al., 1995; Boletta et al., 1997; Lai et al., 1997 Lai et al., , 1998 Tsujie et al., 2000; Foglieni et al., 2000) . Tubules have been targeted by injecting a cationic lipid/DNA complex via the pelvis (Lai et al., 1997 (Lai et al., , 1998 or renal artery (Lai et al., 1997) , or by injecting a cationic polymer/DNA complex via the renal artery (Boletta et al., 1997; Foglieni et al., 2000) . The glomerulus has been targeted by an HVJ-liposome complex via the renal artery (Tomita et al., 1992; Isaka et al., 1993; Arai et al., 1995) . Interstitial fibroblasts have been targeted by injecting an artificial viral envelope-type HVJ-liposome complex in a retrograde manner via the ureter (Tsujie et al., 2000) . It has not been possible to express transgenes in the kidney by injecting naked DNA via the pelvis or via renal artery (Lai et al., 1997) . Kidney-targeted gene transfer using nonviral vectors has resulted in transient gene expression for relatively short periods of time: HVJ-liposome (Tomita et al., 1992; Isaka et al., 1993; Arai et al., 1995) and polyplex (Boletta et al., 1997) for 1 week, artificial viral envelope type HVJ-liposome for 2 weeks (Tsujie et al., 2000) , and lipoplex for 3 weeks (Lai et al., 1997 (Lai et al., , 1998 . Thus, none of the strategies used so far have attained long-term gene expression by kidney-targeted gene transfer. We tested, therefore, the retrograde renal vein injection of naked DNA for the interstitium gene transfer in normal rats to elicit long-term gene expression.
METHODS

Plasmid DNA
We constructed plasmid pCAGGS-Epo (Maruyama et al., 2000) by inserting rat erythropoietin (Epo) cDNA into a unique XhoI site of the pCAGGS expression vector that has the CAG (cytomegalovirus immediate-early enhancer/chicken b-actin hybrid) promoter (Niwa et al., 1991) , and prepared the plasmid using a Qiagen EndoFree plasmid Giga kit (Qiagen GmbH, Hilden, Germany) as described (Maruyama et al., 2000) . We used the empty pCAGGS plasmid as a control.
Rats
Eight-week-old male Wistar rats were purchased from Charles-River Japan Inc. (Tokyo, Japan) and were used for gene transfer.
Plasmid DNA injection techniques
We diluted the plasmid DNA in Ringer's solution. We anesthetized the rats with diethyl ether, performed an incision in the median section of the abdomen, and, immediately before injecting the DNA solution, clamped the left renal vein and artery. Using a 24-gauge SURFLO ® I.V. catheter (Terumo, Tokyo, Japan), we injected the naked DNA solution into the vein and re-established the blood flow immediately after the injection. No incubation time was used in this procedure. Hemostasis was seen at the injected site after applying pressure for 5 sec.
Total tissue DNA extraction and PCR
On day 1, and 24 weeks after the injection, we sacrificed rats that had received 100 mg of pCAGGS-Epo under general anesthesia, and harvested both kidneys, the brain, heart, lungs, liver, spleen, muscle, skin, testes, and blood. We isolated DNA from the tissue samples according to the method of Laird et al. (1991) . We detected pCAGGS-Epo by PCR. We used a pair of primers specific for the cytomegalovirus (CMV) immediateearly enhancer region of pCAGGS-Epo as follows: CMV-1 forward primer, 59-GGGTCATTAGTTCATAGCC-3 9; CMV-2 backward primer, 59-GGCATATGATACACTTGAT-3 9. The PCR protocol consisted of one cycle of 1 min at 95°C, 2 min at 60°C, and 2 min at 74°C, then 29 cycles of 1 min at 94°C, 1 min at 60°C, and 1 min at 72°C, and finally extension for 9 min at 72°C. We analyzed the PCR products by electrophoresis on a 4% agarose gel. The length of the expected products was 215 bp for the CMV immediate-early enhancer DNA of pCAGGS-Epo.
Total tissue RNA extraction and RT-PCR
On day 1, and 24 weeks after the injection, we sacrificed rats that had received 100 mg of pCAGGS-Epo or pCAGGS under general anesthesia, and harvested both kidneys, the brain, heart, lungs, liver, spleen, muscle, skin, and testes. We isolated total RNA from the tissue samples using Isogen (Nippon Gene, Tokyo, Japan). We detected Epo mRNA or glyceraldehyde-3-phosphate dehydrogenase (G3PDH) mRNA by reverse transcription (RT)-PCR as described previously (Maruyama et al., 2000) , using specific primers as follows: Epo backward primer, 59-GCCCAGAGGAATCAGTAGCA-3 9; Epo forward primer, 59-TCTGACTGACCGCGTTACTC-3 9; G3PDH backward primer, 59-TCCACCACCCTGTTGCTGTA-3 9; G3PDH forward primer, 59-ACCACAGTCCATGCCATCAC-3 9. We designed the Epo forward primer to hybridize with the sequence immediately downstream of the transcriptional start site of the CAG promoter. There is an intron between the CAG promoter and the Epo cDNA in pCAGGS-Epo. The primer set for detection of the Epo mRNA was designed to encompass intronic sequences, allowing us to distinguish any possible PCR products from contaminating plasmid DNA or genomic DNA. The primer set for detecting G3PDH mRNA was also designed to span introns. We analyzed the RT-PCR products by electrophoresis on a 4% agarose gel. The lengths of the expected products were 170 bp for Epo mRNA and 452 bp for G3PDH mRNA.
Blood analyses
We measured serum rat Epo levels, hematocrit, reticulocytes, and serum creatinine as described (Maruyama et al., 2000 (Maruyama et al., , 2001 .
X-gal and immunohistochemical staining
pCAGGS-lacZ expresses Escherichia coli b-galactosidase in the cytoplasm (Niwa et al., 1991) . We analyzed kidneys injected with 100 mg of pCAGGS-lacZ histochemically. We harvested the bilateral kidneys for X-gal staining 1 day after the injection, embedded them in Tissue-Tek O.C.T. compound (Sakura Finetechnical Co. Ltd., Tokyo, Japan), and froze them in a mixture of dry ice and acetone. We cut serial sections (5 mm thick) with a cryostat and placed them on glass slides coated with 3-amino-propyltriethoxysilane. We fixed the slices in 1.5% glutaraldehyde at room temperature for 10 min, then washed them three times in cold phosphate-buffered saline (PBS) (5 min/wash), and incubated them in X-gal staining solution containing 1 mg/ml X-gal, 2 mM MgCl 2 , 5 mM K 4 Fe(CN) 6 , 5 mM K 3 Fe(CN) 6 , and 0.5% Nonidet P-40 in PBS (pH 7.4), at 37°C for 3 hr. We stained the sections with X-gal as described (Aihara and Miyazaki, 1998) and counterstained them with Nuclear Fast Red.
To identify the vascular endothelium of the kidney, we immunostained serial sections using EnVision1mouse (Dako, Carpinteria, CA) with the mouse monoclonal antibody RECA-1 (Cosmobio, Tokyo, Japan) (Duijvestijin et al., 1992) , which is reactive to a rat endothelial cell-surface molecule, and counterstained the sections with hematoxylin.
Double-antibody immunofluorescence staining
To locate the site of transgene expression in the PTC, we analyzed kidneys injected with 100 mg of pCAGGS-lacZ. The kidneys at 1 day after injection were cryosectioned at a 5-mm thickness. We fixed the sections in acetone for 5 min at 4 o C and incubated them with rabbit polyclonal anti-E. coli b-galactosidase antibody (1: 200 dilution, Biogenesis, Poole, UK) and the mouse monoclonal rat endothelial cell antibody RECA-1 (1:100 dilution, Cosmobio) for 30 min at room temperature, followed by incubation with fluorescein isothiocyanate (FITC)-conjugated swine anti-rabbit IgG (1:20 dilution, DAKO), or tetramethyl rhodamine isothiocyanate (TRITC)-conjugated goat antimouse IgG 1 (1:20 dilution, Southern Biotechnology Associates, Birmingham, AL) for 30 min at room temperature. We examined the sections using a BX50 system microscope (Olympus Promarketing, Tokyo, Japan). We obtained all micrographs of the immunofluorescence sections using a PM-30 photomicrography system (Olympus Promarketing), and took the pictures using the appropriate filter setting for FITC and TRITC. We used Adobe Photoshop (Adobe Systems, San Jose, CA) for image handling. The transgene expression sites were detected as green fluorescence, and the PTC were detected as red.
Immunoelectron microscopy
To determine further the transgene expression site of the PTC at an ultrastructural level, we analyzed the kidneys injected with 100 mg of pCAGGS-lacZ. One day after the injection, rats were placed under general anesthesia with diethyl ether, and perfused through the aorta with 50 ml of PBS followed by 50 ml of periodate-lysine-paraformaldehyde using a gravity-feed system. The kidneys were further fixed with periodate-lysine-paraformaldehyde fixative for 4 hr at 4°C, treated with 10% sucrose in PBS for 1 hr, embedded in Tissue-Tek O.C.T. compound (Sakura Finetechnical Co. Ltd.), and frozen in hexane at 280°C. Sections (4 mm thick) were cut with a cryostat and incubated with rabbit polyclonal anti-E. coli b-galactosidase antibody (1:800 dilution, Biogenesis) for 30 min at room temperature. After washing in PBS, the sections were incubated with the goat anti-rabbit Ig EnVision1 Peroxidase Rabbit (1:10 dilution, DAKO) for 1 hr. The sections were washed in PBS and incubated with 0.02% diaminobenzidine (DAB) in 0.05 M Tris buffer (pH 7.6) containing 0.01% H 2 O 2 for 3 min. After washing in PBS, the sections were fixed with 2.5% glutaraldehyde for 3 min at room temperature. The sections were washed in PBS, post-fixed with 1% OsO 4 in 0.1 M phosphate buffer (pH 7.2) for 3 min, washed in distilled water, dehydrated in a graded ethanol series, and flat-embedded in Epok 812 (Oken, Tokyo, Japan), which is equivalent to Epon. After polymerization of the Epok 812, we examined the sections by light microscopy, clipped the selected fields, and cut them with an ultramicrotome into ultrathin (100 nm) sections, which were then examined for the DAB-stained sites with an H-600A electron microscope (Hitachi, Ibaragi, Japan).
Renal histology
We harvested the kidneys on days 1 and 7, and 24 weeks after the naked DNA injection, fixed them in 10% buffered formaldehyde, embedded them in paraffin, and processed them for routine light microscopy. We then stained 5-mm sections with periodic acid-Schiff (PAS) for the detection of possible tissue injury due to the gene transfer procedure.
Kidney function
One of the side effects of recombinant human Epo therapy is a decline in renal function in uremic rats (Garcia et al., 1988) . The progression of renal dysfunction in uremic rats is enhanced by electroporation-mediated Epo gene transfer into muscle (Maruyama et al., 2001) . We reasoned that polycythemia induced by the Epo gene transfer probably caused adverse effects on the function of the injected kidney. Therefore, we assessed whether the kidney could function normally immediately after the renal vein injection of 1.0 ml of 100 mg pCAGGS, which does not influence renal function by transgene expression. To examine the function of the injected kidney, we needed to remove the uninjected one, because the uninjected kidney might be able to compensate for functional problems and thus skew our data. Therefore, we injected the left kidney and nephrectomized the right one. Normal, unoperated rats and uninephrectomized rats without DNA injection served as controls. We measured the serum creatinine levels, which is an endogenous marker for kidney function.
Statistical analysis
We presented the data as the mean values 6 the standard deviation of the mean. We analyzed all data using the StatView statistical program for Macintosh (SAS, Cary, NC). We evaluated the statistical significance with the unpaired t-test. We considered p values of ,0.05 to be statistically significant.
RESULTS
Delivery site of India ink
To assess whether a naked DNA solution could reach the PTC by retrograde renal vein injection, we first injected 1.0 ml of India ink. We detected India ink transfer from the vein to the interstitial area and dilated PTC without bleeding (Fig. 1a) . We observed no evidence of India ink transfer into either the glomerular or tubular structures.
Localization of pCAGGS-lacZ gene expression
To determine the transgene expression site, we delivered 100 mg of pCAGGS-lacZ or pCAGGS into the kidneys, and then stained the kidney sections with X-gal. X-gal stained only the interstitium in the cortex area of the pCAGGS-lacZ-injected kidney (Fig. 1b) , but not of the pCAGGS-injected kidney (data not shown). We transferred pCAGGS-lacZ into 5 rats, and have confirmed the reproducibility of the X-gal staining in the injected kidneys. The endothelium of the PTC and glomerular capillaries reacted with a mouse monoclonal anti-rat endothelial cell antibody (RECA-1), thus defining the rat endothelial cells (Fig. 1c) . A comparison between two serial sections (Fig. 1b,c) , one stained with X-gal and the other with RECA-1, shows that the transgene expression was confined to the interstitium containing the PTC.
To clarify the transgene expression site at the interstitium, we next examined the kidney sections by double antibody immunofluorescence staining. The pCAGGS-lacZ expression was detected at sites where several PTC were confluent as broad green fluorescence after immunostaining with a rabbit polyclonal anti-E. coli b-galactosidase antibody followed by FITCconjugated swine anti-rabbit IgG (Fig. 2a) . PTC endothelial cells were detected as thin red fluorescence after immunostaining with RECA-1 followed by TRITC-conjugated goat antimouse IgG 1 (Fig. 2b) . Double-antibody immunofluorescence staining showed an area of yellow fluorescence surrounding yellowish green areas, suggesting that the transgene was expressed in or near a restricted part of the PTC (Fig. 2c) .
The transgene-expressing cells were further examined by immunoelectron microscopy (Fig. 3) , and identified, based on the morphology of renal interstitial cells (Kaissling et al.,1996) , as follows: fibroblasts extend long cytoplasmic processes and adhere with pedicle-like attachments to the basement membranes of the tubules and PTC, macrophages are round in shape and have the prominent lysosomal apparatus, dendritic cells lack these attachments to the basement membranes, and pericytes are found in intimate contact with the PTC and are clearly distinguished from the fibroblasts by the basal lamina continuously surrounding the pericytes. We detected the DAB products exclusively throughout the cytoplasm of the fibroblasts near the PTC (Fig. 3a-c) . The fibroblasts extended long cytoplasmic processes and made close contact with the cytoplasm of the PTC endothelial cells (Fig. 3a-c) and the proximal tubules (Fig.  3a-c) . We observed no evidence of the DAB products in either the endothelium, macrophages, dendritic cells, or pericytes. Thus, these analyses showed that the transgene expression site was the fibroblasts near the PTC. In the following experiments, we used a rat Epo expression plasmid vector pCAGGS-Epo in a reporter assay, because we could easily monitor its physiological effects using serum Epo measurements and red blood cell analyses.
To obtain the approximate injection volume that could be accommodated by a rat kidney, we measured the kidney capacity as follows. We resected the kidney of an 8-week-old male Wistar rat, and placed it inside a 50-ml graduated cylinder containing 30 ml of water. We estimated that the increase in volume was equal to the kidney capacity. The mean kidney capacity was 1.0 6 0.02 ml (n 5 10). We evaluated the effects of varying the injection time (5-60 sec) and volume (0.5-2.0 ml) on the efficiency of gene transfer, measuring the serum Epo levels 1 week before and 1 week after injecting 800 mg of naked DNA. We obtained maximal Epo expression when the DNA solution was injected within 5 sec (Fig. 4a) and with a volume of 1.0 ml (Fig. 4b) . During the injection, the kidney showed slight swelling. We next evaluated the effect of varying the amount of DNA injected using a 5-sec injection time and a volume of 1.0 ml. We observed a dose-response relationship between serum Epo levels and the amount of injected DNA up to 100 mg, and saw substantial levels of Epo gene expression with only 10 mg of DNA (Fig. 4c) .
PCR analysis for the Epo transgene and mRNA in major organs
Although retrograde injection into the renal vein allowed the anatomical targeting of naked DNA to the injected kidney, no other feature of the technique ensured the kidney-specific expression. It was important to examine, therefore, whether the plasmid DNA was transfected into and expressed exclusively in the injected kidney. As shown in Fig. 5 , 1 day after injection, we detected pCAGGS-Epo DNA by PCR only in the left kidney injected with pCAGGS-Epo, but not in any other organs. We also detected the transgene-derived Epo mRNA by RT-PCR only in the left kidneys injected with pCAGGS-Epo (Fig. 6a) , but not in any other organs. We did not detect the transgene-derived Epo mRNA in kidneys injected with pCAGGS (data not shown). However, we detected the control G3PDH mRNA in all the injected kidneys. We obtained similar results by PCR to detect the Epo transgene (data not shown) and by RT-PCR to detect the transgene-derived Epo mRNA (Fig. 6b) at 24 weeks after injection. Thus, the transgene expression by pCAGGS-Epo injected retrogradely via renal vein was confined to the left kidney on day 1 after injection and was maintained for more than 24 weeks.
Time course after pCAGGS-Epo injection
We evaluated the time course of Epo expression when the amount of DNA injected was varied using a 5-sec injection time and a volume of 1.0 ml. Rats were assigned to four groups: three groups were subjected to Epo gene transfer with either 100 mg of pCAGGS-Epo (pCAGGS-Epo 100 mg rats; n 5 3), 30 mg of pCAGGS-Epo (pCAGGS-Epo 30 mg rats; n 5 3), or 2 mg of pCAGGS-Epo (pCAGGS-Epo 2 mg rats; n 5 3), and one group received an injection of 100 mg of pCAGGS (pCAGGS rats; n 5 3). After an injection of 100 mg of pCAGGS-Epo, the serum Epo levels peaked at 208.3 6 71.8 mU/ml at week 5, and gradually decreased to 116.2 6 38.7 mU/ml at week 24 (Fig. 7a) . Until week 24, a similar pattern was obtained at smaller doses of plasmid, 2 mg or 30 mg of pCAGGS-Epo. Transgene-derived Epo secretion caused reticulocytosis (Fig. 7b ). The hematocrit level was much higher in the rats injected even with 2 mg of pCAGGS-Epo than in the pCAGGS-injected rats, for at least 24 weeks, which was the last time point examined (Fig. 7c) . Thus, pCAGGS-Epo transfer continuously produced biologically active Epo, resulting in a significant elevation of the reticulocyte and hematocrit levels in a dose-dependent manner.
KIDNEY-TARGETED NAKED
Histological examination for kidney damage
To evaluate the likelihood of kidney damage, we analyzed kidney sections from rats injected with 1.0 ml of Ringer's solution containing plasmid DNA, and compared them with normal rats that had not been injected (Fig. 8a) . Compared with the kidney sections from normal rats (Fig. 8a) , it was slightly more difficult to identify the endothelial cells of the PTC in the gene-transferred kidney sections on day 1 (Fig. 8b) or day 7 (Fig. 8c) . We found no apparent pathological changes seen in the cortical, medullar, or papillar sections obtained on day 1 (Fig. 8b ) or day 7 (Fig. 8c ) after the injection with pCAGGS-Epo. Similarly, we also found no apparent pathological changes in the sections obtained from rats with an increased hematocrit up to 90% at week 24 (Fig. 8d ) after the injection with pCAGGS-Epo.
Kidney function after injection
The injected kidney function of rats in which the uninjected kidney was removed: Serum creatinine levels increased with growth, and this increase was significantly enhanced by uninephrectomy. The serum creatinine levels were not significantly different between the uninephrectomized groups at any time point, irrespective of DNA injection (Fig. 9) . All the rats survived surgery and the injection procedure and appeared normal. These results demonstrated that the injected kidney could function normally after gene transfer via retrograde renal vein injection.
The kidney function of rats at 24 weeks after pCAGGS-Epo transfer:
We also assessed kidney function of rats with an increased hematocrit up to 90% at 24 weeks after pCAGGS-Epo transfer. There was no difference in the serum creatinine levels between the pCAGGS-Epo 100 mg rats (n 5 3) and the pCAGGS rats (n 5 3) at 1 week before injection: 0.5 6 0.0 mg/dl versus 0.6 6 0.1 mg/dl, respectively. The serum creatinine level at 24 weeks after injection was significantly higher in the pCAGGS-Epo 100 mg rats (n 5 3) than in the pCAGGS rats (n 5 3): 0.6 6 0.1 mg/dl versus 0.5 6 0.1 mg/dl, respectively (p , 0.05). However, the serum creatinine levels in each group were within normal range.
The role of the CAG promoter in kidney-targeted gene expression
Expression plasmid vectors containing the CMV promoter/enhancer region have usually been used in kidney-targeted gene transfer experiments (Zhu et al., 1993; Boletta et al., 1997; Lai et al., 1997 Lai et al., , 1998 Foglieni et al., 2000) . It is important to discriminate between the effects of the difference of the gene transfer methods and those of the promoters utilized. Thus, we also assessed the retrograde renal vein injection method with a CMV-based construct (pCI-Epo). We digested MARUYAMA ET AL. 462 FIG. 5. PCR analysis for pCAGGS-Epo DNA in major organs 1 day after pCAGGS-Epo injection. B, Brain; H, heart; Lu, lung; Li, liver; Sp, spleen; LK, left kidney; RK, right kidney; Mu, muscle; Sk, skin; T, testis; Bl, blood.
FIG. 6.
RT-PCR analysis for Epo mRNA and control G3PDH mRNA in major organs. (a,b) 1 day (a), or 24 weeks (b) after pCAGGS-Epo injection. B, Brain; H, heart; Lu, lung; Li, liver; Sp, spleen; LK, left kidney; RK, right kidney; Mu, muscle; Sk, skin; T, testis. pCAGGS-Epo with EcoRI and obtained a 726-bp rat Epo cDNA fragment. We then constructed the plasmid pCI-Epo by inserting this cDNA fragment into a unique EcoRI site of the pCI expression vector that bears the CMV immediate-early enhancer/promoter (Promega, Madison, WI), and prepared the plasmid as described (Maruyama et al., 2000) . We used the empty pCI plasmid as a control. Rats were assigned to four groups: each group was injected with either 100 mg of pCAGGS-Epo (pCAGGS-Epo rats; n 5 6), 100 mg of pCAGGS (pCAGGS rats; n 5 6), 100 mg of pCI-Epo (pCI-Epo rats; n 5 6), or 100 mg of pCI (pCI rats; n 5 6). We measured the serum Epo levels 1 week before and 1 week after injecting 100 mg of naked DNA. We also confirmed Epo mRNA expression in the kidney injected with 100 mg of pCI-Epo by RT-PCR analysis (data not shown). As shown in Fig. 10 , however, the serum Epo levels were very low with the CMV promoter-based construct (pCI-Epo). On the other hand, the CAG promoter-based construct (pCAGGS-Epo) gave high serum Epo levels. These results clearly demonstrate that the choice of the CAG promoter was greatly instrumental for the success of kidney-targeted gene transfer by the retrograde renal vein injection technique.
DISCUSSION
The present results demonstrate that retrograde renal vein injection of expression plasmid DNA provides an efficient technique for targeting the expression of exogenous genes to the interstitial fibroblasts near the PTC. We found the transgene expression site to be the fibroblasts near the PTC by electron microscopy examination. We observed that the fibroblasts closely contacted the PTC endothelial cells, as seen in Fig. 3b . The structure of the interstitial tissue in the rat kidney, including the observation that the fibroblasts usually have long cytoplasmic processes and adhere with pedicle-like attachments to the basement membranes of PTC, was previously reported by Takahashi-Iwanaga (1991) and Kaissling et al. (1996) . These characteristics of the fibroblasts probably account for the double-antibody immunofluorescence staining pattern that we observed: most of yellowish green area was outside of the yellow area.
The interstitial fibroblast is a key element in the pathogenesis of renal failure. The final common pathway of many progressive renal diseases is the process of fibrosis, which involves the proliferation of renal fibroblasts and the secretion of extracellular matrix by these cells (Kuncio et al., 1991) . The successful gene transfer into fibroblasts in vivo could be of great significance both for the development of antifibrotic strategies and for further understanding of the basic biological mechanisms of fibrosis (Clarke et al., 1999) . Interestingly, the peritubular fibroblasts constitute the major site of Epo production (Bachmann et al., 1993; Maxwell et al., 1993; Bachmann and Ramasubbu, 1997) . The present study is the first to demonstrate that the retrograde renal vein injection technique could deliver an exogenous Epo gene to the endogenous Epo production site.
We performed the retrograde renal vein injection technique without any specific vectors or special devices for gene transfer. The preparation of the naked DNA solution is simple, compared with lipoplex or polyplex preparation. Nephrotoxicity attributable to gene transfer was not apparent either by histological or functional examinations of the injected kidney. Injected polyplex via the left renal artery is not confined to the left kidney and is also entrapped by other organs (Boletta et al., 1997) . In contrast, the transgene expression by our technique is confined to the left kidney without aberrant expression in nontarget organs. Our technique does not require flushing the kidney before the DNA injection (Isaka et al., 1993; Boletta et al., 1997; Foglieni et al., 2000) or an incubation time (Lai et al., 1997; Boletta et al., 1997; Foglieni et al., 2000) . The duration of ischemia caused by the interruption of blood flow during the injection is shorter than 2 min.
As with liver-targeted gene transfer by tail vein injection (Zhang et al., 1999; Liu et al., 1999) , the two critical parameters for successful transgene expression were the injection volume and the injection speed. The optimal injection volume (1.0 ml) for transgene expression was equal to the kidney capacity. The rapid injection of the appropriate volume of DNA solution might contribute to the protection of the plasmid from DNA degradation caused by serum and cellular nucleases (Kawabata et al.,1995) , because the rapid injection results in the direct exposure of the DNA molecules to the PTC before the DNA is mixed with blood.
We have shown that the choice of the CAG promoter is also instrumental for successful transgene expression, and that the CMV promoter is not suitable for kidney-targeted gene transfer by our technique. Recently, several studies have demonstrated that the CAG promoter produces high levels of gene expression in vivo (Kawamoto et al., 2000; Xu et al., 2001) .
Only one (Lai et al.,1998 ) previous study demonstrated a transient physiological effect of gene delivery to kidney: The delivery of the carbonic anhydrase II gene was shown to correct renal tubular acidosis in the carbonic anhydrase II-deficient mouse model. We verified that a transgene delivered by the retrograde renal vein injection technique could exert physiological effects. Epo gene transfer caused erythropoiesis in a dose-dependent manner. The peak serum Epo levels following the renal vein injection of 100 mg of pCAGGS-Epo were greater than or equal to the levels reached following muscle-targeted gene transfer of 400 mg of pCAGGS-Epo by in vivo electroporation (Maruyama et al., 2000 (Maruyama et al., , 2001 . The serum Epo levels at 24 weeks after pCAGGS-Epo transfer by renal vein injection were still one-half of the peak serum Epo levels, a value that was reached 5 weeks after muscle-targeted gene transfer (Maruyama et al., 2001) . Thus, the efficiency of gene transfer and the duration of gene expression after renal vein injection are better than with muscle-targeted gene transfer by in vivo electroporation. The greater surface area of the PTC network may also ensure sufficient gene expression.
Compared with previous reports (Tomita et al., 1992; Isaka et al., 1993; Arai et al., 1995; Boletta et al., 1997; Lai et al., 1997 Lai et al., , 1998 Foglieni et al., 2000; Tsujie et al., 2000) , our technique demonstrates long-term gene expression. Although the lifespan of the fibroblasts is unknown, it is probably long. The localization of the gene transfer to the fibroblasts may be an important factor in long-term gene expression. Thus, our technique could overcome the critical problems of previous kidneytargeted gene transfer strategies by nonviral vectors-low transfection efficiency and short-term expression.
The mechanism underlying the transfer of the naked DNA into the fibroblasts is unclear. The negatively charged PTC (Dworkin et al., 2000) may be refractory to the transfer of negatively charged naked DNA into the endothelium. No incubation time is required for our technique, therefore, hydrostatic pressure (Liu et al., 1999) may be the mechanism underlying the transfer of the naked DNA. Efficient expression may depend on the elevated intravascular hydrostatic pressure caused by the rapid injection of a sufficient volume of fluid, which leads to the transfer of the naked DNA through the PTC endothelium, despite the negative charge. The sharp vascular resistance gradient between the efferent arteriole and the PTC (Lemley and Kriz, 1994) probably played a major role in the blockade of the retrograde stream of injected India ink or naked DNA solution and in the dilation of the PTC, which are the most expandable sites throughout this route, resulting in transgene expression in the fibroblasts. Moreover, these cells may have the ability to take up the naked DNA.
The PTC wall consists of an extremely thin endothelium. Fifty percent of the PTC endothelium is fenestrated, and thus it is highly permeable to water and small solutes (Lemley and Kriz, 1994) . We speculate that the PTC endothelium easily passes Ringer's solution and plasmid DNA under the large hydrostatic pressure. We believe these characteristics of the PTC Our gene therapy technique can easily be applied to humans. Putting the catheter technique to practical use, we can also deliver therapeutic genes to the kidney noninvasively. The present technique could also be useful for ex vivo naked DNA delivery during kidney transplantation. Successful outcomes of transplantation mainly depend on a high suppression of acute rejection (Almond et al., 1993; Hariharan et al., 2000) . The transfer of genes specifically to the fibroblasts near the PTC should be useful for the long-term delivery of therapeutic proteins that suppress either immune cell function or mediators of inflammatory processes.
In conclusion, we have developed a retrograde renal vein injection technique for transferring naked DNA into the kidney of normal rats. The technique is simple, safe, and allows high-level, long-term stable expression and specific gene transfer to the fibroblasts near the PTC, which makes it particularly appealing for potential future applications in humans.
FIG. 9.
Functional analysis of the injected kidney. Uninephrectomized rats with ( s ) or without pCAGGS injection ( u ), and uninjected, unoperated rats ( j ); n 5 6 in each group. *, p , 0.05, and **, p , 0.01 for comparisons with normal rats (comparisons were made at each time point).
FIG. 10.
The role of the CAG promoter in kidney-targeted gene expression. Serum Epo was measured 1 week before ( u ) and 1 week after ( j ) naked DNA injection; n 5 6 in each group. *, p , 0.05, and ****, p , 0.0001 for differences between preand post-injection Epo levels within each group. † † † † , p , 0.0001 comparisons with pCAGGS group (comparisons were made at each time point).
#### , p , 0.0001 for comparisons with pCI group (comparisons were made at each time point). $$$$ , p , 0.0001 for comparisons with pCI-Epo group (comparisons were made at each time point).
endothelium could account for the gene transfer into the fibroblasts nearby and the prevention of the wall rupture during the large hydrostatic pressure caused by the retrograde stream of injected naked DNA solution.
